Comparison of recombinant Trypanosoma cruzi peptide mixtures versus multiepitope chimeric proteins as sensitizing antigens for immunodiagnosis. 2009

Cecilia Camussone, and Verónica Gonzalez, and María S Belluzo, and Nazarena Pujato, and María E Ribone, and Claudia M Lagier, and Iván S Marcipar
Laboratorio de Tecnología Biológica, Universidad Nacional del Litoral, Santa Fe, Argentina.

The aim of this work was to determine the best strategy to display antigens (Ags) on immunochemical devices to improve test selectivity and sensitivity. We comparatively evaluated five Trypanosoma cruzi antigenic recombinant peptides, chose the three more sensitive ones, built up chimeras bearing these selected Ags, and systematically compared by enzyme-linked immunosorbent assay the performance of the assortments of those peptides with that of the multiepitope constructions bearing all those peptides lineally fused. The better-performing Ags that were compared included peptides homologous to the previously described T. cruzi flagellar repetitive Ag (here named RP1), shed acute-phase Ag (RP2), B13 (RP5), and the chimeric recombinant proteins CP1 and CP2, bearing repetitions of RP1-RP2 and RP1-RP2-RP5, respectively. The diagnostic performances of these Ags were assessed for discrimination efficiency by the formula +OD/cutoff value (where +OD is the mean optical density value of the positive serum samples tested), in comparison with each other either alone, in mixtures, or as peptide-fused chimeras and with total parasite homogenate (TPH). The discrimination efficiency values obtained for CP1 and CP2 were 25% and 52% higher, respectively, than those of their individual-Ag mixtures. CP2 was the only Ag that showed enhanced discrimination efficiency between Chagas' disease-positive and -negative samples, compared with TPH. This study highlights the convenience of performing immunochemical assays using hybrid, single-molecule, chimeric Ags instead of peptide mixtures. CP2 preliminary tests rendered 98.6% sensitivity when evaluated with a 141-Chagas' disease-positive serum sample panel and 99.4% specificity when assessed with a 164-Chagas' disease-negative serum sample panel containing 15 samples from individuals infected with Leishmania spp.

UI MeSH Term Description Entries
D007159 Immunologic Tests Immunologic techniques involved in diagnosis. Diagnosis, Immunological,Immunodiagnosis,Diagnosis, Immunologic,Immunologic Diagnosis,Immunologic Test,Immunological Tests,Tests, Immunologic,Diagnoses, Immunologic,Diagnoses, Immunological,Immunodiagnoses,Immunologic Diagnoses,Immunological Diagnoses,Immunological Diagnosis,Immunological Test,Test, Immunologic,Test, Immunological,Tests, Immunological
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000913 Antibodies, Protozoan Immunoglobulins produced in a response to PROTOZOAN ANTIGENS. Protozoan Antibodies
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D000953 Antigens, Protozoan Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered. Protozoan Antigens
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity

Related Publications

Cecilia Camussone, and Verónica Gonzalez, and María S Belluzo, and Nazarena Pujato, and María E Ribone, and Claudia M Lagier, and Iván S Marcipar
January 2006, Biochemical and biophysical research communications,
Cecilia Camussone, and Verónica Gonzalez, and María S Belluzo, and Nazarena Pujato, and María E Ribone, and Claudia M Lagier, and Iván S Marcipar
May 2024, Microbial cell factories,
Cecilia Camussone, and Verónica Gonzalez, and María S Belluzo, and Nazarena Pujato, and María E Ribone, and Claudia M Lagier, and Iván S Marcipar
June 2001, Trends in parasitology,
Cecilia Camussone, and Verónica Gonzalez, and María S Belluzo, and Nazarena Pujato, and María E Ribone, and Claudia M Lagier, and Iván S Marcipar
June 1991, Parasitology today (Personal ed.),
Cecilia Camussone, and Verónica Gonzalez, and María S Belluzo, and Nazarena Pujato, and María E Ribone, and Claudia M Lagier, and Iván S Marcipar
June 2019, PLoS neglected tropical diseases,
Cecilia Camussone, and Verónica Gonzalez, and María S Belluzo, and Nazarena Pujato, and María E Ribone, and Claudia M Lagier, and Iván S Marcipar
January 2019, Methods in molecular biology (Clifton, N.J.),
Cecilia Camussone, and Verónica Gonzalez, and María S Belluzo, and Nazarena Pujato, and María E Ribone, and Claudia M Lagier, and Iván S Marcipar
January 2000, The Journal of infectious diseases,
Cecilia Camussone, and Verónica Gonzalez, and María S Belluzo, and Nazarena Pujato, and María E Ribone, and Claudia M Lagier, and Iván S Marcipar
July 2021, Vaccine,
Cecilia Camussone, and Verónica Gonzalez, and María S Belluzo, and Nazarena Pujato, and María E Ribone, and Claudia M Lagier, and Iván S Marcipar
January 2013, Colloids and surfaces. B, Biointerfaces,
Cecilia Camussone, and Verónica Gonzalez, and María S Belluzo, and Nazarena Pujato, and María E Ribone, and Claudia M Lagier, and Iván S Marcipar
May 2000, Biochemical and biophysical research communications,
Copied contents to your clipboard!